Tecfidera hosrse banner
Tecfidera hosrse banner

Formulary Coverage and $0 Copay for Eligible Patients

Leading coverage can get your patients off to a quick start

TECFIDERA Formulary Coverage
TECFIDERA Formulary Coverage

87% First-Line Coverage1*

TECFIDERA is covered as a first-line relapsing MS (RMS) therapy (unrestricted access) for 87% of commercial patients as of March 2019—more first-line commercial coverage than any other oral RMS therapy.

*Coverage may vary, and there is no guarantee of coverage.



TECFIDERA Copay Program
TECFIDERA Copay Program

$0 Copay Program

The $0 Copay Program provides a monthly supply of TECFIDERA. Eligible patients can enroll for as long as they are treated with TECFIDERA.


Reference: 1.
Biogen, Data on file.